Experimental and Clinical Research Center, Charité Campus Berlin-Buch-CCB, Lindenberger Weg 80, Berlin 13125, Germany.
Nutrients. 2013 Aug 2;5(8):3062-73. doi: 10.3390/nu5083062.
Prevalence of infections by Helicobacter pylori, a pathogen involved in a number of gastrointestinal diseases, remains high in developing countries. Management of infections by eradication is not always an option. Lactobacillus reuteri (L. reuteri) DSMZ17648 (Pylopass™/Lonza) specifically co-aggregates H. pylori in vitro and was shown to reduce ¹³C urea breath test in vivo. In this pilot study, we tried to replicate previous findings in an independent sample and to evaluate effects of spray-drying vs. freeze-drying of cultures. A single-blinded, placebo-controlled study was done in 22 H. pylori positive, asymptomatic adults. H. pylori levels were determined by ¹³C-urea-breath method after 14 days of supplementation, as well as after 6, 12, and 24 weeks follow-up. In the test group, but not in the placebo group, a significant reduction of H. pylori was observed. For the first time, spray-dried cells of L. reuteri DSMZ17648 have been used in a human study and results are in line with the first study results, supplementing with freeze-dried material. This is of special interest as spray-drying results in dead cell material, meaning that the effect of L. reuteri must be independent of its probiotic activity. These results confirm the potential of Pylopass™ as a novel way to reduce the load of H. pylori.
幽门螺杆菌（一种与多种胃肠道疾病相关的病原体）感染的流行率在发展中国家仍然很高。根除感染的管理并非总是可行的选择。罗伊氏乳杆菌（Lactobacillus reuteri）DSMZ17648（Pylopass/Lonza）可特异性地与幽门螺杆菌共聚集，并且在体内被证明可降低 ¹³C 尿素呼气试验。在这项初步研究中，我们试图在独立样本中复制先前的发现，并评估喷雾干燥与冷冻干燥对培养物的影响。在 22 名幽门螺杆菌阳性、无症状的成年人中进行了一项单盲、安慰剂对照研究。在补充 14 天后，通过 ¹³C-尿素呼气法测定幽门螺杆菌水平，随后在 6、12 和 24 周的随访中进行测定。在实验组，但不在安慰剂组中，观察到幽门螺杆菌水平显著降低。首次将罗伊氏乳杆菌 DSMZ17648 的喷雾干燥细胞用于人体研究，结果与首次使用冷冻干燥材料的研究结果一致。这特别有趣，因为喷雾干燥会导致死细胞物质，这意味着罗伊氏乳杆菌的作用必须与其益生菌活性无关。这些结果证实了 Pylopass 作为一种降低幽门螺杆菌负荷的新方法的潜力。
